BioMarin Pharmaceutical Inc. (BMRN) Up 7.4% — Should I Stop Waiting and Start Buying?
BioMarin Pharmaceutical Inc. (BMRN) surged 7.41% this Monday, adding $4.73 to close at $68.54 on the NASDAQ. The session's move is particularly notable because it carries BMRN above its 52-week high of $66.28, set on February 24, 2026 — a meaningful technical development that signals fresh demand and puts the stock in price discovery territory for the first time in months.
Volume came in at approximately 2.55 million shares, running above the 90-day average of roughly 1.99 million. The elevated turnover accompanied the price breakout, lending additional conviction to the move. That combination of price and volume is constructive heading into the week.
Why BioMarin Pharmaceutical Inc. Price is Moving Higher
BioMarin's Monday rally is an extension of the momentum ignited by its strong Q2 report on August 6, with investors continuing to reprice the stock as the full weight of those results settles in. The headline numbers are hard to argue with: adjusted diluted EPS of $1.20 came in well above the $0.95 consensus, a $0.25 beat that reflects genuine operational outperformance rather than accounting tailwinds. Revenue of $989.71 million similarly cleared the bar by $57.68 million against expectations of $932.03 million, marking 20.0% year-over-year growth from $825.41 million in the prior-year period — a striking acceleration for a company whose trailing revenue growth has been considerably more modest.
The product-level detail reinforces the breadth of that top-line strength. VOXZOGO — one of BioMarin's highest-profile growth assets — generated $253 million in the quarter, up 14% year over year, while PALYNZIQ delivered an even sharper 27% gain to $135 million. Newly acquired GALAFOLD contributed $106 million, and the combined POMBILITI and OPFOLDA franchise added $30 million, demonstrating that the company's recent portfolio expansion is already producing meaningful revenue. Management followed those results by raising 2026 revenue guidance to $3.875 billion–$3.925 billion from $3.825 billion–$3.925 billion, lifting the VOXZOGO outlook to $1.0 billion–$1.05 billion from $975 million–$1.025 billion, and tightening adjusted EPS guidance higher to $4.90–$5.10 from $4.85–$5.05. A fresh analyst target increase arriving after the report added further fuel to the rally, pulling additional buyers into a stock that had clearly been undervalued relative to what the business was delivering.
The repricing unfolding over the past several sessions reflects investors reassessing the gap between where BMRN was trading and where the fundamentals now point. A Q2 beat of this magnitude — across both earnings and revenue — combined with raised full-year guidance gives the market a clear anchor for reassessment, and Monday's volume-supported breakout above the 52-week high suggests that reassessment still has room to run.
What is the BioMarin Pharmaceutical Inc. Rating - Should I Buy?
Weiss Ratings assigns BMRN a C- rating. Current recommendation is Hold. The C- reflects a mixed fundamental picture in which genuine strengths coexist with meaningful areas of concern — a profile that calls for discipline rather than aggressive positioning, even after a session as compelling as Monday's.
On the positive side, the Excellent Growth Index is the standout, supported by the kind of revenue acceleration visible in the Q2 results and consistent with a company expanding its rare-disease product portfolio through both organic growth and acquisition. The Excellent Solvency Index reinforces that BioMarin is managing its balance sheet with care — a critical quality for a pharmaceutical company that funds expensive clinical programs and integrates acquired assets simultaneously. The Good Efficiency Index adds a constructive layer, with ROE of 4.48% representing early-stage earnings leverage for a specialty biopharma navigating significant investment cycles across multiple therapeutic areas.
Where the C- grade reflects genuine caution is in the Weak Total Return Index and Weak Volatility Index. The Total Return picture acknowledges that BMRN has struggled to consistently translate operational progress into investor returns over time, while the Weak Volatility Index signals that the stock can move sharply in both directions — Monday's 7.41% surge being a vivid illustration. A forward P/E of 46.56 is demanding for a company carrying a profit margin of 8.28% and trailing revenue growth of 2.83% on a full-year basis, even as the Q2 acceleration argues that the underlying trajectory is improving. That valuation gap between current multiples and current profitability is the central tension that keeps the rating at Hold rather than Buy.
Within the Health Care sector, BioMarin sits alongside Pfizer Inc. (PFE, C-) and Danaher Corporation (DHR, C-), and below Bristol-Myers Squibb Company (BMY, C+), Merck & Co., Inc. (MRK, C), and Thermo Fisher Scientific Inc. (TMO, C). That peer positioning reflects a company with real competitive assets in rare disease but not yet the sustained profitability and return profile that would warrant a higher rating tier.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) is a Health Care company focused exclusively on developing and commercializing therapies for patients with serious rare genetic diseases. The company's approach is built around conditions where the underlying biology is well understood, patient populations are identifiable, and the unmet need is acute — a combination that historically supports pricing power and durable revenue streams once a therapy achieves regulatory approval and clinical adoption. BioMarin's deep expertise in enzyme replacement, gene therapy, and substrate modulation has allowed it to build a portfolio of marketed products that address conditions with limited or no prior treatment options.
The commercial portfolio is anchored by VOXZOGO, a CNP analog approved for achondroplasia — the most common form of short-limb dwarfism — which is scaling rapidly as the company expands its geographic reach and patient identification efforts. PALYNZIQ addresses phenylketonuria, a metabolic disorder that requires strict dietary management without intervention, and has built a growing patient base among those unable to manage the condition through diet alone. The addition of GALAFOLD, an oral chaperone therapy for Fabry disease, and the POMBILITI plus OPFOLDA combination for Pompe disease through acquisition, has broadened the company's rare disease franchise meaningfully, adding revenue streams that reduce dependence on any single asset.
BioMarin competes on scientific depth, regulatory experience, and the ability to navigate the complex reimbursement and patient access dynamics that define the rare disease market globally. Its intellectual property portfolio around each approved therapy, combined with the difficulty of replicating the clinical evidence packages required for approval in small patient populations, creates meaningful barriers to competition. The company also maintains an active pipeline, which is essential in rare disease where the next approved product can materially reset the long-term revenue trajectory.
Investor Outlook
BioMarin Pharmaceutical Inc. (BMRN) carries a Weiss Rating of C- (Hold), reflecting a business with genuine growth momentum and a strong balance sheet that is still working toward the consistent profitability and return profile needed to drive a higher rating. Investors will be watching whether the Q2 acceleration in VOXZOGO and PALYNZIQ sustains into the second half of the year and whether management delivers on its raised 2026 guidance — progress on both fronts could be the catalyst that shifts the fundamental picture. See full rankings of all C--rated Health Care stocks inside the Weiss Stock Screener.
--